申请人:Boehringer Ingelheim Pharmaceuticals, Inc.
公开号:US20030225270A1
公开(公告)日:2003-12-04
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
1
本发明涉及一种新型的可逆抑制剂,其化学式为(I),(II),(Ia)和(Ib),可抑制S、K、F、L和B型卡特普西蛋白。本发明还涉及制备这种新型化合物的方法。这些化合物可用于治疗自身免疫性疾病。